Pharmac’s decision to fund continuous glucose monitors and automated insulin delivery systems for the approximately 18,000 people who currently live with type 1 diabetes in Aotearoa New Zealand is good news.
The decision comes after years of advocacy from patient groups and clinicians.
But there are problems within the broader system – particularly around workforce shortages – that mean full patient access to training on how to use the insulin pumps will likely take years.
